Prognosis of a malignant phenotype of obesity defined by a cardiac biomarker in hypertension: the Japan Morning Surge-Home Blood Pressure study.
Biomarkers
Cardiovascular event
High-sensitive cardiac troponin T
Hypertension
Obesity
Journal
Hypertension research : official journal of the Japanese Society of Hypertension
ISSN: 1348-4214
Titre abrégé: Hypertens Res
Pays: England
ID NLM: 9307690
Informations de publication
Date de publication:
19 Oct 2023
19 Oct 2023
Historique:
received:
16
03
2023
accepted:
26
09
2023
revised:
28
07
2023
medline:
20
10
2023
pubmed:
20
10
2023
entrez:
19
10
2023
Statut:
aheadofprint
Résumé
Obesity with increased high-sensitive cardiac troponin T (hs-cTnT) has been reported to be more likely to progress cardiovascular disease (CVD) events, which suggests that hs-cTnT may identify a "malignant" phenotype of obesity. We classified 3513 hypertensive patients from the Japan Morning Surge-Home Blood Pressure (J-HOP) study into groups based on body mass index (BMI) (normal weight: <25 kg/m
Identifiants
pubmed: 37857765
doi: 10.1038/s41440-023-01468-8
pii: 10.1038/s41440-023-01468-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to The Japanese Society of Hypertension.
Références
NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387:1377–96.
doi: 10.1016/S0140-6736(16)30054-X
Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a disease. Med Clin North Am. 2018;102:13–33.
doi: 10.1016/j.mcna.2017.08.004
pubmed: 29156181
Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016;118:1752–70.
doi: 10.1161/CIRCRESAHA.115.306883
pubmed: 27230640
Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98–107.
doi: 10.1016/j.metabol.2018.10.011
pubmed: 30399375
Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925–32.
doi: 10.1016/j.jacc.2008.12.068
pubmed: 19460605
Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab. 2012;97:2482–8.
doi: 10.1210/jc.2011-3475
pubmed: 22508708
pmcid: 3387408
Stefan N, Häring HU, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1:152–62.
doi: 10.1016/S2213-8587(13)70062-7
pubmed: 24622321
Welsh P, Preiss D, Hayward C, Shah ASV, McAllister D, Briggs A, et al. Cardiac troponin T and troponin I in the general population. Circulation. 2019;139:2754–64.
doi: 10.1161/CIRCULATIONAHA.118.038529
pubmed: 31014085
pmcid: 6571179
Huang J, Liu M, Su E, Yu P, Jiang H, Zhao J, et al. Elevated circulating high-sensitive cardiac troponin T and cardiac remodeling in obesity. BMC Cardiovasc Disord. 2021;21:620.
doi: 10.1186/s12872-021-02445-0
pubmed: 34963447
pmcid: 8714432
Boudina S, Sena S, O’Neill BT, Tathireddy P, Young ME, Abel ED. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation. 2005;112:2686–95.
doi: 10.1161/CIRCULATIONAHA.105.554360
pubmed: 16246967
Abel ED, O’Shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol. 2012;32:2068–76.
doi: 10.1161/ATVBAHA.111.241984
pubmed: 22895668
pmcid: 3646067
Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ Res. 2007;101:335–47.
doi: 10.1161/CIRCRESAHA.107.150417
pubmed: 17702980
Park SK, Ryoo JH, Oh CM, Choi JM, Kang JG, Lee JH, et al. Effect of overweight and obesity (defined by Asian-Specific Cutoff Criteria) on left ventricular diastolic function and structure in a general Korean population. Circ J. 2016;80:2489–95.
doi: 10.1253/circj.CJ-16-0625
pubmed: 27773890
Ndumele CE, Coresh J, Lazo M, Hoogeveen RC, Blumenthal RS, Folsom AR, et al. Obesity, subclinical myocardial injury, and incident heart failure. JACC Heart Fail. 2014;2:600–7.
doi: 10.1016/j.jchf.2014.05.017
pubmed: 25443112
pmcid: 4345168
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157–63.
doi: 10.1016/S0140-6736(03)15268-3
Pan WH, Yeh WT. How to define obesity? Evidence-based multiple action points for public awareness, screening, and treatment: an extension of Asian-Pacific. Asia Pac J Clin Nutr. 2008;17:370–4.
pubmed: 18818155
Brouwers FP, van Gilst WH, Damman K, van den Berg MP, Gansevoort RT, Bakker SJ, et al. Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community based cohort. Circ Heart Fail. 2014;7:723–31.
doi: 10.1161/CIRCHEARTFAILURE.114.001185
pubmed: 25057112
Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017;135:e1054–e1091.
doi: 10.1161/CIR.0000000000000490
pubmed: 28446515
Hoshide S, Yano Y, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, et al. Morning and evening home blood pressure and risks of incident stroke and coronary artery disease in the Japanese general practice population: the Japan Morning Surge-Home Blood Pressure study. Hypertension. 2016;68:54–61.
doi: 10.1161/HYPERTENSIONAHA.116.07201
pubmed: 27160200
WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO Tech Rep Ser; 2000. p. 1–253.
Anwar YA, Giacco S, McCabe EJ, Tendler BE, White WB. Evaluation of the efficacy of the Omron HEM-737 IntelliSense device for use on adults according to the recommendations of the Association for the Advancement of Medical Instrumentation. Blood Press Monit. 1998;3:261–5.
pubmed: 10212364
de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503–12.
doi: 10.1001/jama.2010.1768
pubmed: 21139111
pmcid: 5621378
Doi Y, Ninomiya T, Hata J, Hirakawa Y, Mukai N, Ikeda F, et al. N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in a Japanese community: the Hisayama study. Arterioscler Thromb Vasc Biol. 2011;31:2997–3003.
doi: 10.1161/ATVBAHA.111.223669
pubmed: 21921261
Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab. 2004;89:2569–75.
doi: 10.1210/jc.2004-0165
pubmed: 15181025
Karelis AD. Metabolically healthy but obese individuals. Lancet. 2008;372:1281–3.
doi: 10.1016/S0140-6736(08)61531-7
pubmed: 18929889
Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30-year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018;6:714–24.
doi: 10.1016/S2213-8587(18)30137-2
pubmed: 29859908
Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev. 2014;15:504–15.
doi: 10.1111/obr.12157
pubmed: 24661566
pmcid: 4309497
Arnlöv J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010;121:230–6.
doi: 10.1161/CIRCULATIONAHA.109.887521
pubmed: 20038741
Flint AJ, Hu FB, Glynn RJ, Caspard H, Manson JE, Willett WC, et al. Excess weight and the risk of incident coronary heart disease among men and women. Obesity (Silver Spring). 2010;18:377–83.
doi: 10.1038/oby.2009.223
pubmed: 19629058
Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci. 2001;321:225–36.
doi: 10.1097/00000441-200104000-00003
pubmed: 11307864
Marchio P, Guerra-Ojeda S, Vila JM, Aldasoro M, Victor VM, Mauricio MD. Targeting early atherosclerosis: a focus on oxidative stress and inflammation. Oxid Med Cell Longev. 2019;1:8563845.
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–30.
doi: 10.1172/JCI200319451
pubmed: 14679177
pmcid: 296998
Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–46.
doi: 10.1146/annurev-physiol-021909-135846
pubmed: 20148674
Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017;13:633–43.
doi: 10.1038/nrendo.2017.90
pubmed: 28799554
Suthahar N, Meems LMG, Groothof D, Bakker SJL, Gansevoort RT, van Veldhuisen DJ, et al. Relationship between body mass index, cardiovascular biomarkers, and incident heart failure. Eur J Heart Fail. 2021;23:396–402.
doi: 10.1002/ejhf.2102
pubmed: 33443299
Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594–600.
doi: 10.1161/01.CIR.0000112582.16683.EA
pubmed: 14769680
Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, Lainchbury JG, Richards AM, Ordoñez-Llanos J, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med. 2007;167:400–47.
doi: 10.1001/archinte.167.4.400
pubmed: 17325303
Parcha V, Patel N, Kalra R, Suri SS, Arora G, Wang TJ, et al. Obesity and Serial NT-proBNP levels in guided medical therapy for heart failure with reduced ejection fraction: insights from the GUIDE-IT trial. J Am Heart Assoc. 2021;10:e018689.
doi: 10.1161/JAHA.120.018689
pubmed: 33754794
pmcid: 8174357